Evaluation of occupational exposure to antiblastic drugs in an Italian Hospital Oncological Department

Journal of Occupational Health

Volumn 50, Issue 1, 2008, Pages 48-56

  Castiglia, Loredana ^a   Miraglia, Nadia ^a,b   Pieri, Maria ^a,b   Simonelli, Angela ^b   Basilicata, Pascale ^b   Genovese, Giuliana ^b   Guadagni, Rossella ^b   Acampora, Antonio ^a   Sannolo, Nicola ^b   Scafarto, Maria Virginia ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

5 fluorouracil; Cyclophosphamide; Ifosfamide; Occupational exposure; Statistical evaluation

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC ANTIMETABOLITE; CYCLOPHOSPHAMIDE; FLUOROURACIL; IFOSFAMIDE;

ARTICLE; DRUG FORMULATION; ENVIRONMENTAL MONITORING; EQUIPMENT; FEMALE; GAS CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOSPITAL SUBDIVISIONS AND COMPONENTS; HUMAN; ITALY; METHODOLOGY; NURSE; OCCUPATIONAL EXPOSURE; PROTECTIVE CLOTHING; STANDARD; UTILIZATION REVIEW;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, ALKYLATING; CHROMATOGRAPHY, GAS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLOPHOSPHAMIDE; DRUG COMPOUNDING; ENVIRONMENTAL MONITORING; EQUIPMENT CONTAMINATION; FEMALE; FLUOROURACIL; GLOVES, PROTECTIVE; HOSPITAL UNITS; HUMANS; IFOSFAMIDE; ITALY; NURSES; OCCUPATIONAL EXPOSURE;

EID: 40349086903     PISSN: 13419145     EISSN: 13489585     Source Type: Journal    
DOI: 10.1539/joh.50.48     Document Type: Article

References (40)

1. Thrasher JB, Miller GJ and Wettlaufer JN: Bladder leiomyosarcoma following cyclophosphamide therapy for lupus nephritis. J Urol 143, 119-121 (1990)
2. Dedrick RL and Morrison PF: Carcinogenic potency of alkylating agents in rodents and humans. Cancer Res 52, 2464-2467 (1992)
3. Otto T and Rubben H: Prevention of bladder cancer. Urologe A 43, 562-564 (2004)
4. International Agency for Research on Cancer, IARC. Monographs on the evaluation of carcinogenic risks to humans. Some antineoplastic and immunosuppressive agents. Vol. 26. Lyon CEDEX 08 (France): 1998. (online), available from 〈http://wwwcie.iarc.fr/htdocs/monographs/vol26/ cyclophosphamide.html〉, (accessed 2007-12-27).
5. Spiers A, Chikkappa G and Wilbur H: Hemorrhagic cystitis after low-dose cyclophosphamide. Lancet 1, 1213-1214 (1983)
6. Sherins RJ and DeVita VT Jr: Effect of drug treatment for lymphoma on male reproductive capacity. Studies of men in remission after therapy. Ann Intern Med 79, 216-220 (1973)
7. Kohn KW, Hartley JA and Mattes WB: Mechanisms of DNA sequence selective alkylation of guanine-N7 positions by nitrogen mustards. Nucleic Acids Res 24, 10531-10548 (1987)
8. Falck K, Grohn P, Sorsa M, Vaino H, Heinonen E and Holsti LR: Mutagenicit y in urine of nurses handling cytostatic drugs. Lancet 9, 1250-1251 (1979)
9. Sessink P, Cerna M and Rossner P: Urinary cyclophosphamide excretion and chromosomal aberrations in peripheral blood lumphocytes after occupational exposure to antineoplastic agents. Mutat Res 309, 193-199 (1994)
10. Fuchs J, Hengstler JG, Jung D, Hiltl G, Konietzko J and Oesch F: DNA damage in nurses handling antineoplastic agents. Mutat Res 342, 17-23 (1995)
11. Sorsa M, Hemminki K and Vainio H: Occupational exposure to anticancer drug-potential and real hazard. Mutat Res 154, 135-149 (1985)
12. Undeger I, Basaran N, Kars A and Guc D: Assessment of DNA Damage in nurses handling antineoplastic drugs by the alkaline COMET assay. Mutat Res 439, 277-285 (1999)
13. Skov T, Maarup B, Olsen J, Rorth M, Wintherreik H and Lynge E: Leukaemia and reproductive outcome among nurses handling antineoplastic drugs. Br J Ind Med 49, 855-861 (1992)
14. Sessink P, Kroese E, van Kraner H and Bos R: Cancer risk assessment health care workers occupationally exposed to cyclophosphamide. Int Arch Occup Environ Health 67, 317-323 (1995)
15. Bouyer J, Saurel-Cubizolles M, Grenier C, Aussel L and Job-Spira N: Ectopic pregnancy and occupational exposure of hospital personnel. Scand J Work Environ Health 24, 98-103 (1998)
16. Selevan SG and Hornung RW: Antineoplastic drugs and spontaneous abortion in nurses. N Engl J Med 314, 1050 (1985)
17. McDonald AD, McDonald JC, Cherry NM, Cote R, Lavoi J, Nolin AD and Robert D: Congenital defects and work in pregnancy. Br J Ind Med 45, 581-588 (1988)
18. Stuecker I and Caillard JF: Risk of spontaneous abortion among nurses handling antineoplastic drugs. Scand. J Work Environ Health 16, 102-107 (1990)
19. Valanis BG, Vollmer WM, Labuhn KT and Glass AG: Occupational exposure to antineoplastic agents and self-reported infertility among nurses and pharmacists. J Occup Environ Med 39, 574-580 (1997)
20. Sorsa M and Anderson D: Monitoring of occupational exposure to cytostatic anticancer agents. Mutat Res 355, 253-261 (1996)
21. Sessink PJ, Kroese ED, van Kranen HJ and Bos RP: Cancer risk assessment for health care workers occupationally exposed to cyclophosphamide. Int Arch Occup Environ Health 67, 317-323 (1995)
22. Sessink PJ and Bos RP: Drugs hazardous to healthcare workers. Evaluation of methods for monitoring occupational exposure to cytostatic drugs. Drug Saf 20, 347-359 (1999)
23. Apostoli P, Clonfero E, Cottica D, Bergamaschi A, Moccaldi R, Draicchio F, Tranfo G, Sannolo N and Sossai D: Criteria and methods for the study of occupational exposure to antineoplastic agents. Med Lav 87, 230-254 (1996)
24. Canadian Society of Hospital Pharmacists: Guidelines for the handling of hazardous pharmaceuticals. Can J Hosp Pharm 34, 126-128 (1981)
25. G.U. n. 236, 7 October 1999. Sicurezza e Igiene del Lavoro. Difesa dagli agenti cancerogeni [Safety and Hygiene. National Document] (in Italian).
26. D.Lgs. n. 626, 19 September 1994. Miglioramento della salute e della sicurezza dei lavoratori durante il lavoro [Legislative Decree. National Document]. (online), available from 〈http://www.amblav.it〉, (accessed 2007-12-27, in Italian).
27. D.Lgs. n. 66, 25 February 2000. Protezione dei lavoratori circa i rischi derivanti dall'esposizione ad agenti cancerogeni o mutageni [Legislative Decree. Workers protection about risks from the exposure to carcinogenic or mutagenic agents]. (online), available from 〈http://www.amblav.it〉, (accessed 2007-12-27, in Italian).
28. Goodman I. Clinical practice guidelines: the administration of cytotoxic chemotherapy. Technical report, eds. Oxford: Royal College of Nursing, 1998.
29. Health & Safety Executive. Workshop on cytotoxic drugs. London: Rose Court, 1997.
30. Hedmer M, Georgiadi A, Bremberg ER, Jonsson BA and Eksborg S: Surface contamination of cyclophosphamide packaging and surface contamination with antineoplastic drugs in a hospital pharmacy in Sweden. Ann Occup Hyg 49, 629-637 (2005)
31. Mason HJ, Blair S, Sams C, Jones K, Garfitt SJ, Cuschieri SJ and Baxter PJ: Exposure to antineoplastic drugs in two UK hospital pharmacy units. Ann Occup Hyg 49, 603-610 (2005)
32. Acampora A, Castiglia L, Miraglia N, Pieri M, Soave C, Liotti F and Sannolo N: A case study: surface contamination of cyclophosphamide due to working practices and cleaning procedures in two italian hospitals. Ann Occup Hyg 49, 611-618 (2005)
33. Sannolo N, Miraglia N, Biglietto M, Acampora A and Malorni A: Determination of cyclophosphamide and ifosphamide in urine at trace levels by gas chromatography/tandem mass spectrometry. J Mass Spectrom 34, 845-849 (1999)
34. Soave C, Giuliari C, Bartolucci GB, Carrieri M, Festa D, Sannolo N, Miraglia N, Acampora A and Viotti PL: Cyclophosphamide environmental contamination in drug reconstitution units in twenty one Italian hospitals. Eur J Pharmacy 9, 81-84 (2003)
35. Food and Drug Administration Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM), U.S. Department of Health and Human Services, Guidance for Industry-Bioanalytical Method Validation, May 2001. (online), available from 〈http://www.fda.gov/CDER/GUIDANCE/4252fnl. htm〉, (accessed 2007-12-27).
36. Crauste-Manciet S, Sessink PJ, Ferrari S, Jomier JY and Brossard D: Environmental contamination with cytotoxic drugs in healthcare using positive air pressure isolators. Ann Occup Hyg 49, 619-628 (2005)
37. Ziegler E, Mason HJ and Baxter PJ: Occupational exposure to cytotoxic drugs in two UK oncology wards. Occup Environ Med 59, 608-612 (2002)
38. Sessink PJ, Anzion RB, Van den Broek PH and Bos RP: Detection of contamination with antineoplastic agents in a hospital pharmacy department. Pharm Weekbl Sci 14, 16-22 (1992)
39. Minoia C, Turci R, Sottani C, Schiavi A, Perbellini L, Angeleri S, Draicchio F and Apostoli P: Application of high performance liquid chromatography/tandem mass spectrometry in the environmental and biological monitoring of health care personnel occupationally exposed to cyclophosphamide and ifosfamide. Rapid Commun Mass Spectrom 12, 1485-1493 (1998)
40. Schmaus G, Schierl R and Funck S: Monitoring surface contamination by antineoplastic drugs using gas chromatography-mass spectrometry and voltammetry. Am J Health Syst Pharm 59, 956-961 (2002)